Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03367741 | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | Sep 9, 2026 | clinicaltrials |
| NCT03606967 | Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 |
| clinicaltrials |
| NCT04001829 | Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer | active not recruiting | Phase 2 | 249 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04080804 | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | active not recruiting | Phase 2 | 80 | Dan ZandbergOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04592237 | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04838548 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 87 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04899908 | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases | recruiting | Phase 2 | 134 | Brigham and Women's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05039892 | Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 50 | 3D Medicines (Beijing) Co., Ltd.INDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT05287945 | Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 75 | Oncorena ABINDUSTRY | 5 | Sep 9, 2026 | clinicaltrials |
| NCT05343325 | The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC | active not recruiting | Phase 2 | 25 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05570253 | A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | recruiting | Phase 2 | 55 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05715931 | Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | active not recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05774899 | CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC | recruiting | Phase 1 / Phase 2 | 32 | Michael J. Dennis, MDOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05925530 | Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)(MDT-BRIDGE) | active not recruiting | Phase 2 | 142 | AstraZenecaINDUSTRY | 11 | Sep 9, 2026 | clinicaltrials |
| NCT05968326 | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC(IMCODE003) | active not recruiting | Phase 2 | 260 | Genentech, Inc.INDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT06037980 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence(PURITY) | recruiting | Phase 2 / Phase 3 | 300 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06184516 | Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy | recruiting | Phase 2 | 127 | University of FloridaOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06315010 | Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis(REPOSE) | recruiting | Phase 2 | 20 | MedSIROTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06780137 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | recruiting | Phase 1 / Phase 2 | 327 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT07147231 | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07256223 | A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07668154 | A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants | recruiting | Phase 2 | 120 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07808515 | A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC) | not yet recruiting | Phase 2 | 135 | Regeneron PharmaceuticalsINDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03937830 | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | active not recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04107077 | Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer | recruiting | Phase 2 | 21 | University of ChicagoOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04997902 | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | completed | Phase 1 / Phase 2 | 45 | Kura Oncology, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer(CANOPY) | active not recruiting | Phase 2 | 47 | Rana McKay, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05789082 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation(KRAScendo 170) | recruiting | Phase 1 / Phase 2 | 320 | Hoffmann-La RocheINDUSTRY | 18 | Sep 8, 2026 | clinicaltrials |
| NCT05801029 | A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations(OSTARA) | active not recruiting | Phase 2 | 60 | AstraZenecaINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06861452 | Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma(SNIPER) | recruiting | Phase 1 / Phase 2 | 9 | EIR Biotherapies s.r.l.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07130786 | Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases | recruiting | Phase 2 | 150 | Ayal A. Aizer, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07132190 | Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction | recruiting | Phase 2 | 60 | Ayal A. Aizer, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07189793 | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study(OHAI-NMIBC-01) | not yet recruiting | Phase 2 | 106 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels(OLIGOMETS) | recruiting | Phase 2 | 54 | Yale UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07718243 | Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC(BLAZE) | recruiting | Phase 1 / Phase 2 | 62 | Institute of Cancer Research, United KingdomOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07779694 | 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer | not yet recruiting | Phase 2 | 51 | Zhejiang UniversityOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07806110 | Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer | active not recruiting | Phase 2 | 62 | The First Hospital of Jilin UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806292 | Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study(ABH-uHCC) | recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807163 | A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC(FORTIFI-FLEX) | recruiting | Phase 2 | 160 | Bicara TherapeuticsINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807722 | Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC | not yet recruiting | Phase 2 | 29 | Hubei Cancer HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07808138 | RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer(RADICAL-IO) | not yet recruiting | Phase 2 | 30 | The Netherlands Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT02479698 | Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02642042 | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03608631 | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | recruiting | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04597359 | To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Sep 4, 2026 | clinicaltrials |
| NCT05192798 | Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC | recruiting | Phase 2 | 128 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05198830 | Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery | suspended | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials